Esperion Therapeutics, Inc. (ESPR)
Pre-market:
| Previous close | 2.3000 |
| Open | 2.3100 |
| Bid | 2.5600 x 1800 |
| Ask | 2.6000 x 4000 |
| Day's range | 2.2750 - 2.6000 |
| 52-week range | 0.7000 - 3.4000 |
| Volume | |
| Avg. volume | 7,243,091 |
| Market cap | 490.701M |
| Beta (5Y monthly) | 0.89 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.9000 |
| Earnings date | 30 Jul 2024 - 05 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 7.41 |
GlobeNewswireEsperion Receives Five Year Patent Extension for Bempedoic Acid, Contained in NEXLETOL® and NEXLIZET®
ANN ARBOR, Mich., May 14, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) announced today that the U.S. Patent and Trademark Office (USPTO) issued a U.S. Patent Term Extension (PTE) certificate for bempedoic acid, which is contained in NEXLETOL® (bempedoic acid) Tablets and NEXLIZET® (bempedoic acid and ezetimibe) Tablets. The certificate extends the term of U.S. Patent No. 7,335,799 by five years through December 3, 2030. The PTE certificate was granted under the patent restoration provisions
- GlobeNewswire
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
ANN ARBOR, Mich., May 10, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that on May 8, 2024, the Company granted 16 new employees 62,300 restricted stock units (RSUs) under Esperion’s 2017 Inducement Equity Incentive Plan. The 2017 Inducement Equity Incentive Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee or non-employee director of Esperion (or following a bona fide period of non-employment), as an inducement materia
ZacksEsperion (ESPR) Q1 Earnings Beat, Stock Up on Strong Revenues
Esperion's (ESPR) first-quarter earnings and sales beat estimates on the back of better-than-expected collaboration revenues.
